Evaluation of depressive mood and cognitive functions in patients with acromegaly under somatostatin analogue therapy

Alibas H., Uluc K., Koytak P. K., UYGUR M. M., Tuncer N., Tanridag T., ...More

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, vol.40, no.12, pp.1365-1372, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 40 Issue: 12
  • Publication Date: 2017
  • Doi Number: 10.1007/s40618-017-0722-y
  • Journal Name: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1365-1372
  • Keywords: Acromegaly, Depressive mood, Cognitive functions, QUALITY-OF-LIFE, GROWTH-FACTOR-I, LONG-TERM CURE, PITUITARY-TUMORS, HORMONE EXCESS, RADIOTHERAPY, IMPAIRMENT, BRAIN, COMPLICATIONS, DYSFUNCTION
  • Recep Tayyip Erdoğan University Affiliated: No

Abstract

Aims Acromegaly is caused by a pituitary adenoma that releases excess growth hormone (GH) and a concomitant increase in insulin-like growth factor 1 (IGF-1). Acromegaly results not only in phenotypic changes, but also in neurologic complications as peripheral neuropathy and cognitive dysfunction. This study aimed to compare depressive mood and cognitive function in patients with acromegaly and in healthy controls as well as to determine the factors underlying cognitive dysfunction in the acromegalic patients.